Conduit Pharmaceuticals (NASDAQ:CDT) Releases Quarterly Earnings Results

Conduit Pharmaceuticals (NASDAQ:CDT) released its earnings results on Friday. The company reported ($20.33) EPS for the quarter, Zacks reports.

Conduit Pharmaceuticals Stock Up 15.9 %

Shares of Conduit Pharmaceuticals stock opened at $0.89 on Friday. The stock’s fifty day moving average is $1.90 and its two-hundred day moving average is $7.07. Conduit Pharmaceuticals has a 52 week low of $0.73 and a 52 week high of $379.00.

Conduit Pharmaceuticals Company Profile

Conduit Pharmaceuticals Inc, a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.